BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Duchenne muscular dystrophy

  Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids

  Since Elevidys’ accelerated approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory children. New results, presented Friday, show mobility improvements in 8- to 9-year-old patients after one year of follow-up.

  May 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  BioMarin Expands Enzyme Expertise With $270M Inozyme Buy

  The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.

  May 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  C-suite

  UPDATED: With Novo CEO’s Sudden Exit, Analysts Worry ‘There’s Something Pretty Wrong Here’

  Over Lars Fruergaard Jørgensen’s eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares have taken a turn since mid-2024, falling by half in one year.

  May 16, 2025

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  RNA editing

  Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline

  Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

  May 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval

  The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are intolerant to platinum chemotherapy or whose disease has progressed.

  May 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

  May 16, 2025

   · 

  7 min read
• Press Releases

  Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

  May 16, 2025

   · 

  10 min read
• Press Releases

  Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer’s Disease

  May 16, 2025

   · 

  6 min read
• Press Releases

  SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

  May 16, 2025

   · 

  4 min read
• Press Releases

  Molecular Partners Reports Financial Results and Highlights from Q1 2025

  May 16, 2025

   · 

  12 min read